Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Express Scripts
Argus Health
UBS
Fish and Richardson
Mallinckrodt
Queensland Health
Medtronic

Generated: July 23, 2018

DrugPatentWatch Database Preview

ORAVERSE Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Oraverse patents expire, and what generic alternatives are available?

Oraverse is a drug marketed by Septodont Holding and is included in one NDA. There are five patents protecting this drug.

This drug has thirty-three patent family members in twenty countries.

The generic ingredient in ORAVERSE is phentolamine mesylate. There are four drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the phentolamine mesylate profile page.
Summary for ORAVERSE
Drug patent expirations by year for ORAVERSE
Pharmacology for ORAVERSE
Medical Subject Heading (MeSH) Categories for ORAVERSE
Synonyms for ORAVERSE
134P201
2-[N-(m-Hydroxyphenyl)-p-toluidinomethyl]imidazoline Methanesulfonate
2-[N-(m-Hydroxyphenyl)-p-toluidinomethyl]imidazoline, methanesulfonate
3-[(2-imidazolin-2-ylmethyl)(4-methylphenyl)amino]phenol, methanesulfonic acid
3-[[(4,5-Dihydro-1H-imidazol-2- yl)methyl](4-methylphenyl)-amino]phenol mesylate
3-[[(4,5-Dihydro-1H-imidazol-2-yl)methyl](4-methylphenyl)-amino]phenol mesylate
3-[4,5-dihydro-1H-imidazol-2-ylmethyl-(4-methylphenyl)amino]phenol; methanesulfonic acid
3-[N-(2-Imidazolin-2-ylmethyl)-p-toluidino]phenol methanesulphonate
3-[N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-4-methyl-anilino]phenol; methanesulfonic acid
3-[N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-4-methylanilino]phenol; methanesulfonic acid
3-[N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-4-methylanilino]phenol;methanesulfonic acid
4CA-1013
50-60-2 (Parent)
65-28-1
A828197
A835046
AB0014005
AB2000443
AC-7472
AC1L3M27
AKOS007930193
AN-8957
AS-13800
BC200362
C17H19N3O.CH4O3S
C18H23N3O4S
CCG-222286
CCRIS 9022
CHEMBL1200873
CPD000059054
CS-2419
CTK8G2357
D00509
DR002120
DTXSID60215315
EINECS 200-604-6
EU-0100982
FT-0603267
HE375279
HMS2233A24
HMS3263E05
HMS3373D03
HMS3655B13
HY-B0362A
I14-0396
J10339
K062
KS-00000XQY
Lopac-P-7561
LP00982
LS-104726
m-(N-(2-Imidazolin-2-ylmethyl)-p-toluidino)phenol monomethanesulfonate (salt)
MCULE-3770473461
METHANESULFONIC ACID; PHENTOLAMINE
MFCD00134201
MLS000069487
MLS001076484
MolPort-003-959-154
NCGC00016195-01
NCGC00016195-02
NCGC00094282-01
NCGC00261667-01
NV-101
Opera_ID_1599
P 7561
P1985
Phenol, 3-(((4,5-dihydro-1H-imidazol-2-yl)methyl)(4-methylphenyl)amino)-, monomethanesulfonate (salt)
Phenol, m-(N-(2-imidazolin-2-ylmethyl)-p-toluidino)-, monomethanesulfonate (salt)
Phentolamine (mesylate)
phentolamine mesilate
Phentolamine mesilate (JAN/INN)
Phentolamine mesilate [INN:BAN]
Phentolamine mesilate for system suitability, European Pharmacopoeia (EP) Reference Standard
Phentolamine mesilate, European Pharmacopoeia (EP) Reference Standard
Phentolamine mesylate
Phentolamine mesylate (USP)
Phentolamine mesylate [USP]
Phentolamine Mesylate, pharmaceutical secondary standard; traceable to USP, PhEur
Phentolamine mesylate, United States Pharmacopeia (USP) Reference Standard
Phentolamine methanesulfonate
Phentolamine methanesulfonate salt
Phentolamine methanesulfonate salt, >=98% (TLC), powder
Phentolamine methanesulphonate
REGID_for_CID_91430
Regitin mesylate
Regitin methanesulphonate
Regitine (TN)
Regitine mesylate
Regitine methanesulfonate
s2038
SAM002703130
SCHEMBL40852
SMR000059054
SR-01000000055
SR-01000000055-3
ST057364
Tox21_500982
UNII-Y7543E5K9T
Vasofem
Vasomax
VZ33629
W-104799
Y7543E5K9T
Z-Max

US Patents and Regulatory Information for ORAVERSE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Septodont Holding ORAVERSE phentolamine mesylate INJECTABLE;INJECTION 022159-001 May 9, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Septodont Holding ORAVERSE phentolamine mesylate INJECTABLE;INJECTION 022159-001 May 9, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Septodont Holding ORAVERSE phentolamine mesylate INJECTABLE;INJECTION 022159-001 May 9, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Septodont Holding ORAVERSE phentolamine mesylate INJECTABLE;INJECTION 022159-001 May 9, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Non-Orange Book US Patents for ORAVERSE

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,432,401 Local anesthetic methods and kits ➤ Sign Up
7,261,889 Local anesthetic methods and kits ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
QuintilesIMS
Harvard Business School
Cerilliant
Mallinckrodt
Moodys
Baxter
Cantor Fitzgerald
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.